创新干预:神经退行性疾病治疗中的后生物和精神生物
Mandeep Kumar Gupta1, Kanupriya Chauhan2, Snigdha Bhardwaj3
1Department of Pharmaceutical Chemsitry, Moradabad Educational Trust Group of Institutions Faculty of Pharmacy, Moradabad, 244001, Uttar Pradesh, India. mandeepkrgupta@gmail.com.
Probiotics and antimicrobial proteins
|June 27, 2025
概括
后生菌和精神生菌通过向肠-大脑轴,显示出神经保护的前景. 这些微生物组衍生化合物可以通过减少炎症和氧化应激来帮助管理神经退行性疾病.
科学领域:
- 微生物学 微生物学
- 神经学 神经学
- 临床营养学 临床营养学
背景情况:
- 神经退行性疾病带来越来越多的挑战,目前没有治愈治疗方法.
- 肠道微生物组和肠-大脑轴是新兴的治疗点.
- 后生物 (微生物代谢物) 和精神生物 (具有精神健康益处的益生菌) 提供了新的神经保护策略.
研究的目的:
- 分析支持后生菌和精神生菌用于神经疾病预防和管理的数据.
- 探索它们调节炎症,氧化应激和肠道屏障完整性的机制.
- 讨论饮食和营养对治疗结果的影响.
主要方法:
- 关于神经保护中后生菌和精神生菌的科学文献的综述.
- 检查增强认知功能和减少神经退行症的微生物菌株和代谢物.
- 分析饮食在强化治疗效果中的作用.
主要成果:
- 后生物和精神生物调节涉及神经保护的关键通路.
- 特定的微生物干预措施在增强认知功能方面表现出有效性.
- 饮食和营养可以显著影响这些干预措施的治疗潜力.
结论:
- 后生物和精神生物药物代表了管理神经退行性疾病的有希望的途径.
- 将基于微生物组的策略与营养相结合,有可能改善患者的治疗结果.
- 针对基于微生物组的个性化治疗需要进一步的研究和临床翻译.
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
430
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
430
Drugs for Treatment of Diarrhea-Predominant IBS
312
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
312
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Drugs for Treatment of Constipation-Predominant IBS
351
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
351


